| # | Drug | Count |
|---|---|---|
| 0 | DULOXETINE | 32 |
| 1 | DULOXETINE HYDROCHLORIDE | 32 |
| 2 | VENLAFAXINE HYDROCHLORIDE | 25 |
| 3 | VENLAFAXINE | 22 |
| 4 | RITUXIMAB | 17 |
| 5 | LEVETIRACETAM | 16 |
| 6 | CLONAZEPAM | 13 |
| 7 | LEVETIRACETAM IN SODIUM CHLORIDE | 13 |
| 8 | LEVETIRACETAM INJECTION | 13 |
| 9 | LEVETIRACETAM ORAL | 13 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | ETHOSUXIMIDE | 7 | 0.0028 |
| 1 | BEDAQUILINE FUMARATE | 2 | 0.0014 |
| 2 | METHYLENE BLUE | 2 | 0.0013 |
| 3 | VINBLASTINE SULFATE | 2 | 0.0010 |
| 4 | LISDEXAMFETAMINE DIMESYLATE CAPSULES | 4 | 0.0008 |
| 5 | CEPHALEXIN | 10 | 0.0005 |
| 6 | DULOXETINE HYDROCHLORIDE | 32 | 0.0004 |
| 7 | EPOETIN ALFA-EPBX | 1 | 0.0004 |
| 8 | NEVIRAPINE | 4 | 0.0004 |
| 9 | MARAVIROC | 1 | 0.0004 |
| # | Drug class | Count |
|---|---|---|
| 0 | Benzodiazepine [EPC] | 28 |
| 1 | Corticosteroid [EPC] | 19 |
| 2 | Anti-epileptic Agent [EPC] | 18 |
| 3 | CD20-directed Cytolytic Antibody [EPC] | 17 |
| 4 | Alkylating Drug [EPC] | 13 |
| 5 | Atypical Antipsychotic [EPC] | 12 |
| 6 | Mood Stabilizer [EPC] | 12 |
| 7 | Azole Antifungal [EPC] | 10 |
| 8 | Platinum-based Drug [EPC] | 10 |
| 9 | Calcineurin Inhibitor Immunosuppressant [EPC] | 9 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CCR5 Co-receptor Antagonist [EPC] | 1 | 0.0004 |
| 1 | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC] | 8 | 0.0004 |
| 2 | Anticholinergic [EPC] | 5 | 0.0003 |
| 3 | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 5 | 0.0002 |
| 4 | CD30-directed Immunoconjugate [EPC] | 2 | 0.0002 |
| 5 | CTLA-4-directed Blocking Antibody [EPC] | 7 | 0.0001 |
| 6 | Noncompetitive AMPA Glutamate Receptor Antagonist [EPC] | 1 | 0.0001 |
| 7 | Cholinergic Muscarinic Antagonist [EPC] | 5 | 0.0001 |
| 8 | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 5 | 0.0001 |
| 9 | Provitamin D2 Compound [EPC] | 3 | 0.0001 |